SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · IEX Real-Time Price · USD
4.600
+0.380 (9.00%)
Mar 28, 2024, 3:25 PM EDT - Market closed

SAB Biotherapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Current2022202120202019
Market Capitalization
4225340--
Market Cap Growth
--92.52%---
Enterprise Value
4416309-41
PE Ratio
-1.21-1.35-19.80--
PS Ratio
10.231.065.58--
PB Ratio
2.750.828.81--
P/FCF Ratio
-2.83-0.99-37.91--
P/OCF Ratio
-2.88-1.08170.89--
EV/Sales Ratio
10.770.685.07-0.080.38
EV/EBITDA Ratio
-1.52-1.08-20.30-0.21-0.16
EV/EBIT Ratio
-1.31-0.88-18.31-0.22-0.15
EV/FCF Ratio
-3.02-0.64-34.441.65-0.13
Debt / Equity Ratio
0.300.190.220.21-3.31
Debt / EBITDA Ratio
-0.20-0.39-0.560.38-0.93
Debt / FCF Ratio
-0.40-0.23-0.95-2.99-0.78
Quick Ratio
0.261.371.803.001.98
Current Ratio
0.341.471.903.122.01
Asset Turnover
0.100.420.881.48-
Interest Coverage
-82.62-61.06-57.2243.88-19.97
Return on Equity (ROE)
-120.40%-53.50%-44.20%109.60%-
Return on Assets (ROA)
-69.20%-32.60%-24.90%54.00%-
Return on Capital (ROIC)
-135.93%-78.18%-28.46%43.61%-162.67%
Earnings Yield
-64.97%-73.83%-5.05%--
FCF Yield
-27.84%-100.65%-2.64%--
Buyback Yield / Dilution
-21.79%-59.20%-1.21%23.30%-
Total Shareholder Return
-21.79%-59.20%-1.21%23.30%-
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).